Switzerland: Kinarus Therapeutics strengthens financial position with convertible loan

Kinarus Therapeutics Holding, a SIX-listed clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, has signed a strategic convertible loan agreement for a CHF1.5m (US$1.7m) investment by ChaoDian Investment Management Co (CDIM), a China-based investment company. This agreement forms the basis for discussions on the introduction, development and commercialization of KIN001…

You must be a HMI Subscriber to view this content.

Subscribe Now »